Overall, our study highlights the potential clinical application of SGLT2 inhibition in the prevention of obesity and related metabolic diseases, such as insulin resistance, NAFLD, and diabetes. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.